<DOC>
	<DOC>NCT02375139</DOC>
	<brief_summary>This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 tablets).</brief_summary>
	<brief_title>A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age between 19 to 45, healthy male subjects(at screening) Body weight between 55kg 90kg, BMI between 18.0 27.0 FPG 60125mg/dL glucose level(at screening) Volunteer who totally understands the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress. Volunteer who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary, endocrine, hematooncology, cardiology, mental disorder) Volunteer who had GI tract disease(Crohn's disease, ulcer, acute or chronic pancreatitis) or surgery(appendectomy, hernioplasty are excluded) Volunteer who had drug(Aspirin, antibiotics) hypersensitivity reaction Subject who already participated in other trials in 2 months Subject who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>